Harvard Bioscience (HBIO) Amortization of Deferred Charges (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Amortization of Deferred Charges data on file, last reported at $446000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 240.46% year-over-year to $446000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 321.91% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 304.28% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $446000.0, down from $624000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for HBIO reached as high as $624000.0 in Q4 2025 and fell as low as $70000.0 in Q1 2022.
• Historically, Amortization of Deferred Charges has averaged $156176.5 across 5 years, with a median of $70000.0 in 2022.
• Across the five-year window, Amortization of Deferred Charges changed 0.0% in 2022 and surged 536.73% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $70000.0 in 2022, then changed by 0.0% to $70000.0 in 2023, then soared by 40.0% to $98000.0 in 2024, then jumped by 536.73% to $624000.0 in 2025, then declined by 28.53% to $446000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $446000.0 in Q1 2026, $624000.0 in Q4 2025, and $357000.0 in Q3 2025.